Home » Pharmaceuticals & Biotech » US Opioids market is of $8b in size and of which extended release formulations contribute 50% says the new report on pain management therapeutics
Market Reports Center’s repository has new report titled “Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era”. Report has two segments covering; Opioids – Novel Abuse deterrent Formulation Technologies & Pipeline drugs, and Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain.

Report discusses a number of novel delivery technologies employed in formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.

Download the sample pages of report at https://marketreportscenter.com/request-sample/377098

According to report Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).

Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create “Abuse Deterrent Era” in the coming time.

Check the discount on report at https://marketreportscenter.com/request-discount/377098

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.

New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.

US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of this market in US and Europe in coming years.

Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioid use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.

Table of Contents

1. Executive Summary
2. Management of Pain
3. FDA Schedule for controlled substances and advantage of Schedule III over II
4. FDA Perspective on Abuse deterrent formulations (Opioids)
5. Approved Abuse deterrent Formulations by FDA – Development, label claim, Technology and current prescription trend
6. Abuse Deterrent Technology Platforms employed in marketed drugs and pipeline
7. Pipeline analysis of Novel Technologies and new mechanisms in Pain management.
8. Late stage pipeline developments in neuropathic pain

Some of the pharmaceutical players profile in report are AbbVie, AcelRx pharma, Acorda Therapeutics, Actavis, Biogen, Convatech, Eli Lilly, Glenmark, Johnson and Johnson, Pfizer and many more.

Get your copy today at https://marketreportscenter.com/reports/377098/pain-management-new-discoveries-and-treatment-options-in-abuse-deterrent-era

About Market Reports Center:

Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable.

Market Reports Center currently has more than 3,00,000 plus titles and 40+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, and Construction.

Media Contact
Company Name: Market Reports Center
Contact Person: Sam Collins
Email: info@marketreportscenter.com
Phone: 1-646-883-3044
Address:201, Daulat Complex, Opp Veritas, Baner Rd, Baner
City: Pune
State: Maharashtra
Country: United States
Website: https://marketreportscenter.com/reports/377098/pain-management-new-discoveries-and-treatment-options-in-abuse-deterrent-era

Comments are closed.